Search
BARD1 is focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer.

Bard1 raises $7.5m, makes board changes

Cancer-focused medical technology company BARD1 Life Sciences has raised around $7.5 million via a share placement and rights issue, and has appointed two non-executive directors to its board.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Top 10 Shareholders

Source: Morningstar

Total Shareholder Return as at 28/06/19

1 year TSR5 year TSR
21stAdveritas198%-11%
38thBARD1 Life Sciences114%5%
666thCervantes Corporation-56%33%
686thFBR-58%22%
839thNeurotech International-87%
731 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

12/07/19
$10k Issued
12/07/19
$100k Issued
12/07/19
$100k Issued
Total value as at the date of the transaction
Source: Morningstar

Revenue

158th↑BARD1 Life Sciences$357k
171st↓FBR$78k
172nd↑Cervantes Corporation$76k
174th↓Adveritas$73k
175th↑Neurotech International$67k
198 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer